title: [Analysis of 32 cases of acute leukemia with abnormality of chromosome 7].
abstract: OBJECTIVE
  To explore the incidence and prognostic significance of chromosome 7 anomaly in acute leukemia.
  
  
  METHODS
  Conventional cytogenetic analysis of R-band was used to detect the abnormalities of chromosome 7 in 410 acute leukemia patients.
  
  
  RESULTS
  Thirty-two cases (7.8%) with abnormalities of chromosome 7, of which 19 (59.4%) had -7/7q-; 3(9.4%) had t(7;11); and the rest had other abnormalities such as der(7), +7, t(2;7), t(5;7), t(7;9), t(7;8) and dic(1;7). The incidence of -7/7q- in M0, M1 and M2 was higher than that in other subtypes of acute myeloid leukemia (AML). Twenty cases had additional cytogenetic aberrations, such as t(9;22) with -7, +8, -5. In 30 cases treated with chemotherapy, 11 cases acquired complete remission (CR) and the CR rate was lower than that for all concurrent cases of acute leukemia(36.7% vs 65.8%); the CR rate of AML with -7/7q- was lower than that of AML with normal karyotype(25% vs 55.6%). There was no difference in the CR rate between acute lymphocytic leukemia(ALL) with -7/7q- and ALL with normal chromosome (57.1% vs 77.8%), but 4 cases with -7/7q- which attained complete remission for a time relapsed early. In other 11 patients with additional chromosome 7 aberration, only 4 patients acquired CR.
  
  
  CONCLUSIONS
  -7/7q- was the frequent aberration in chromosome 7 anomaly, which was often detected in M0, M1 and M2. It might be associated with the pathogenesis of acute leukemia; the patients with chromosome 7 anomaly had poorer prognosis.
authors.affiliation: Department of Hematology, the First Affiliated Hospital, Medical College, Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, 310003 P. R. China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Lu
authors.forename: Jie
authors.initials: J
authors.lastname: Jin
authors.forename: Zhi-mei
authors.initials: ZM
authors.lastname: Chen
authors.forename: Ji-yu
authors.initials: JY
authors.lastname: Lou
authors.forename: Wei-lai
authors.initials: WL
authors.lastname: Xu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002869:Chromosome Aberrations; D002897:Chromosomes, Human, Pair 7; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics*; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone